Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: B.REVERE who wrote (3947)	7/6/1998 11:26:00 AM
From: Frostman	Read Replies (1) \| Respond to of 9523

this from WSJ interactive:<<Pfizer Completes Phase I Trial Of Corvas Intl Stroke Therapy Dow Jones Newswires SAN DIEGO -- Pfizer Inc. (PFE) completed a Phase I clinical trial of an anti-inflammatory candidate for treating ischemic stroke that was discovered by Corvas International Inc. (CVAS). When the study began in February, Corvas received a $1-million milestone payment from Pfizer, which has exclusive rights to develop and make the therapeutic agent. In a press release Monday, Corvas said up to $24 million in potential milestone payments remain in the program. The biopharmaceutical company is also eligible to receive royalty payments on future sales of related products. The candidate, neutrophil inhibitory factor, has been shown to reduce collateral brain injury following a stroke in animal models.>> EOM